Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABBV-243 · 1 trial · 1 indication
An AE is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.
Maximum observed serum concentration (Cmax) of ABBV-243
Area under the serum concentration-time curve (AUC) from time 0 to the time of last measurable concentration (AUCt) of ABBV-243
AUC from time 0 to infinite time (AUCinf) of ABBV-243
Terminal phase elimination rate constant of ABBV-243
Terminal phase elimination half-life of ABBV-243
Confirmed Positive ADA Results.
| Arm | Type | Description |
|---|---|---|
| Group 1: ABBV-243 or Placebo | EXPERIMENTAL | Participants will receive either a single intravenous (IV) dose of ABBV-243, or the placebo equivalent, on Day 1 |
| Group 2: ABBV-243 or Placebo | EXPERIMENTAL | Participants will receive either a single intravenous (IV) dose of ABBV-243, or the placebo equivalent, on Day 1 |
| Group 3: ABBV-243 or Placebo | EXPERIMENTAL | Participants will receive either a single intravenous (IV) dose of ABBV-243, or the placebo equivalent, on Day 1 |
| Group 4: ABBV-243 or Placebo | EXPERIMENTAL | Participants will receive either a single intravenous (IV) dose of ABBV-243, or the placebo equivalent. on Day 1 |
| Group 5: ABBV-243 or Placebo | EXPERIMENTAL | Participants will receive either a single subcutaneous (SC) dose of ABBV-243, or the placebo equivalent, on Day 1 |
| Group 6: ABBV-243 or Placebo | EXPERIMENTAL | Participants will receive either a single subcutaneous (SC) dose of ABBV-243, or the placebo equivalent, on Day 1 |
| Group 7: ABBV-243 or Placebo | EXPERIMENTAL | Han Chinese participants will receive either a single intravenous (IV) dose of ABBV-243, or the placebo equivalent. on Day 1 |
| Group 8: ABBV-243 or Placebo | EXPERIMENTAL | Japanese participants will receive either a single intravenous (IV) dose of ABBV-243, or the placebo equivalent. on Day 1 |
| Name | Type | Description |
|---|---|---|
| ABBV-243 | DRUG | Intravenous (IV) Infusion |
| Placebo | DRUG | Intravenous (IV) Infusion |
Inclusion Criteria: * Individuals between 18 and 60 years of age inclusive at the time of Screening. * BMI is ≥ 18.0 to ≤ 32.0 kg/m2 after rounding to the tenth's decimal at Screening. BMI is calculated as weight in kg divided by the square of height measured in meters. * Females, Non-Childbearing ...
ABBV-243 is an investigational small molecule drug being developed by AbbVie Inc. It is currently in Phase 1 clinical development. The specific disease or condition it is intended to treat has not been disclosed, and the only study listed for it to date is a Phase 1 trial in healthy adult volunteers.
ABBV-243 is being developed by AbbVie Inc., which trades on the New York Stock Exchange under the ticker ABBV. AbbVie is the sponsor of the Phase 1 study evaluating the compound. No partner or collaborator is identified for this asset.
ABBV-243 is in Phase 1 clinical development. It is an investigational small molecule and has not been approved by the FDA. One Phase 1 trial is currently recruiting, and no completed trials are listed for the compound.
ABBV-243 is being studied in one Phase 1 trial, NCT07306754, titled a Phase 1 study to evaluate the safety and pharmacokinetics of ABBV-243 in healthy adults. The trial is recruiting, is randomized, double blind, and controlled, and plans to enroll 66 participants in the United States.
The Phase 1 trial NCT07306754 enrolls healthy adult volunteers age 18 years and older, and accepts participants of all sexes. It is a randomized, double blind, controlled study of 66 participants conducted in the United States, and it is currently recruiting.
The therapeutic use of ABBV-243 has not been disclosed. The compound is in Phase 1 development, and its only listed trial, NCT07306754, is conducted in healthy volunteers rather than in patients with a specific disease. No approved indication exists for ABBV-243.